Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethinylestradiol/norelgestromin transdermal - Johnson & Johnson

Drug Profile

Ethinylestradiol/norelgestromin transdermal - Johnson & Johnson

Alternative Names: Contraceptive patch - Johnson & Johnson; Ethinylestradiol/17-deacetyl norgestimate transdermal - Johnson & Johnson; Ethinylestradiol/RWJ 10553; Evra; Evra™; Ortho Evra

Latest Information Update: 04 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen-Cilag; Ortho-McNeil
  • Class Alkylated estrogenic steroids; Hormonal contraceptives; Norpregnatrienes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 20 Aug 2019 Janssen initiates a phase I trial in Healthy volunteers in Belgium and Netherlands (Transdermal, Patch) (NCT04017195)
  • 12 Jul 2019 Janssen plans a phase I trial in Healthy volunteers in Belgium, Germany and Netherlands (Transdermal, Patch) (NCT04017195)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top